Talha Badar, Hematology/Oncology Specialist at Mayo Clinic, shared a post on X:
“2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party
Takeaways
- The update standardizes MRD assessment across AML subtypes and aligns recommendations with the ELN 2022 genetic risk classification, recognizing that MRD interpretation must be mutation-specific and context dependent.
- MRD should be measured at: Diagnosis (to establish baseline marker), After induction / after 2 cycles of chemotherapy, End of treatment, Before allogeneic transplant, During follow-up
- New framework for MRD interpretation: MRD burden: negative | low-level (MRD-LL) | positive Clinical response: optimal | warning | high risk of treatment failure This helps contextualize MRD dynamics rather than relying only on numeric thresholds.
- Recommended MRD technologies include: Multiparameter flow cytometry (MFC), qPCR/dPCR for markers such as NPM1 or fusion genes, Ultra-high-sensitivity NGS (e.g., FLT3-ITD) to detect very low disease burden.”
Title: 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party
Authors: Jacqueline Cloos, Peter Valk, Christian Thiede, Konstanze Döhner, Gail Roboz, Brent Wood, Roland Walter, Sa Wang, Agnieszka Wierzbowska, Andrew Wei, David Wu, François Vergez, Adriano Venditti, Bert van der Reijden, Arjan van de Loosdrecht, Ing Tiong, Felicitas Thol, Marion Subklewe, Christophe Roumier, Tom Reuvekamp, Farhad Ravandi, Claude Preudhomme, Adriana Plesa, Jad Othman, Gert Ossenkoppele, Yishai Ofran, Aguirre Mimoun, Luca Maurillo, Agata Majchrzak, David de Leeuw, Wolfgang Kern, Dennis Kim, Maura Ikoma-Colturato, Lukas Haaksma, Monica Guzman, Michaela Feuring, Barbara Depreter, Anna Czyz, Veit Bücklein, Constance Baer, Costa Bachas, Sylvie Freeman, Francesco Buccisano, Christopher Hourigan, Richard Dillon, Michael Heuser
Read the Full Article.
Other articles featuring Talha Badar on OncoDaily.
